成大生物(688739) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 358,395,731.16, a decrease of 1.73% compared to CNY 364,709,258.37 in the same period last year[5] - Net profit attributable to shareholders was CNY 72,218,005.25, down 11.35% from CNY 81,463,701.09 year-on-year[5] - Total revenue for Q1 2025 was CNY 358,395,731.16, a decrease of 1.1% compared to CNY 364,709,258.37 in Q1 2024[19] - Net profit for Q1 2025 was CNY 72,218,005.25, down 11.3% from CNY 81,463,701.09 in Q1 2024[19] - Operating profit for Q1 2025 was ¥88,612,647.35, down 48.6% from ¥172,340,409.52 in Q1 2024[29] - Net profit for Q1 2025 was ¥80,196,541.41, a decline of 45.0% compared to ¥145,908,490.99 in Q1 2024[29] Cash Flow - The net cash flow from operating activities increased by 15.77% to CNY 38,495,548.95, compared to CNY 33,252,685.73 in the previous year[5] - Cash flow from operating activities for Q1 2025 is ¥38,495,548.95, an increase of 15.5% compared to ¥33,252,685.73 in Q1 2024[22] - The net cash flow from operating activities for Q1 2025 was ¥25,693,550.62, down 67.2% from ¥78,399,476.34 in Q1 2024[31] - The company reported a cash inflow from sales of goods and services of ¥306,402,043.44 in Q1 2025, down 13.4% from ¥353,763,410.47 in Q1 2024[22] - The net cash flow from investment activities is -¥573,711,775.49, a significant decrease from ¥27,185,195.69 in the previous period[23] - The company reported a net cash outflow from investing activities of ¥528,225,792.41 in Q1 2025, compared to a smaller outflow of ¥50,151,806.51 in Q1 2024[31] Assets and Liabilities - Total assets at the end of the reporting period were CNY 10,080,623,416.18, reflecting a slight increase of 0.29% from CNY 10,051,587,266.31 at the end of the previous year[6] - Total assets as of March 31, 2025, were CNY 10,080,623,416.18, slightly up from CNY 10,051,587,266.31 at the end of 2024[17] - Total liabilities decreased to CNY 445,937,459.82 from CNY 489,119,315.20, a reduction of 8.8%[17] - Total liabilities decreased to ¥328,712,007.83 from ¥364,821,816.98, indicating a reduction of 9.9%[27] - The company’s total equity increased to CNY 9,634,685,956.36 from CNY 9,562,467,951.11, reflecting a growth of 0.8%[17] - The total equity increased to ¥10,062,485,088.05 from ¥9,982,288,546.64, reflecting a growth of 0.8%[27] Research and Development - Research and development expenses totaled CNY 86,826,788.11, representing 24.23% of operating revenue, a decrease of 1.92 percentage points from 26.15%[6] - Research and development expenses for Q1 2025 were CNY 51,861,758.56, down 12.1% from CNY 58,997,464.13 in Q1 2024[19] - Research and development expenses increased significantly to ¥63,157,263.29 in Q1 2025, compared to ¥19,874,594.47 in Q1 2024, reflecting a growth of 217.5%[29] Shareholder Information - The company reported a total of 25,451 common shareholders at the end of the reporting period[9] - The controlling shareholder, Liaoning Chengda, holds 54.67% of the company's shares, with a change in control from a state-owned entity to a private management company[11] - The company has completed the legal procedures for a mandatory general offer to all shareholders due to the change in control[11] Earnings Per Share - The basic and diluted earnings per share were both CNY 0.18, a decrease of 10% from CNY 0.20 in the same period last year[5] - Basic and diluted earnings per share for the current period are both ¥0.18, down from ¥0.20 in the previous period, reflecting a 10% decline[20] Cash and Cash Equivalents - Cash and cash equivalents decreased to CNY 3,961,121,082.99 from CNY 4,496,464,173.92 as of December 31, 2024, a decline of 11.9%[15] - Cash and cash equivalents at the end of the period are ¥3,962,685,051.08, down from ¥4,587,507,490.87 in the previous year, indicating a decrease of 13.6%[23] - The beginning balance of cash and cash equivalents was 4,421,617,178.42, while the ending balance was 3,918,934,767.46[32] Accounting Standards - The company will first implement new accounting standards starting from 2025, which will affect the financial statements[32]